Estudo de braço único, fase 1/2 | Glofitamabe para linfoma recidivante ou refratário de grandes células B.

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário no Twitter

Glofitamab, a bifunctional antibody, was given to 154 patients with relapsed or refractory DLBCL. Complete response occurred in 39%; most of these responses were ongoing at 12 months. Cytokine release syndrome was common. https://t.co/FWavXlkVXD pic.twitter.com/F4eyYja2E4

— NEJM (@NEJM) December 11, 2022